Back to search

Article

Predicting early bactericidal activity of tuberculosis drug combinations using a translational pharmacokinetic-pharmacodynamic modeling approach

2026-02-02

Abstract excerpt

Phase IIa pulmonary tuberculosis (TB) trials typically assess the early bactericidal activity (EBA) of monotherapy for over 14 days. However, few studies have evaluated drug combinations, even though optimal monotherapy doses may not directly translate to combinations. Translational pharmacokinetic-pharmacodynamic (PK-PD) modeling has shown promise in predicting human treatment responses based on preclinical monot...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
873c3ea6-3fce-56fe-96e4-ecdbf402ebe0
DOI
10.64898/2026.01.29.702705
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Predicting early bactericidal activity of tuberculosis drug combinations using a translational pharmacokinetic-pharmacodynamic modeling approachDOI 10.64898/2026.01.29.702705
Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosisSemantic proximity
A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts in vivo interactions of tuberculosis drugsSemantic proximity
Lesion penetration predicts tuberculosis regimen success: a validated translational tool for de-risking late-stage drug developmentSemantic proximity
A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts <i>in vivo</i> interactions of tuberculosis drugsSemantic proximity
Establishing a framework for human dose prediction in anti-tuberculosis drug developmentSemantic proximity
Systematic measurement of combination drug landscapes to predict <i>in vivo</i> treatment outcomes for tuberculosisSemantic proximity
The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.Semantic proximity
A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.Semantic proximity
Modelling treatment response in tuberculosis early bactericidal activity trialsSemantic proximity
Transcriptomic signatures predict regulators of drug synergy and clinical regimen efficacy against TuberculosisSemantic proximity
Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosisSemantic proximity
Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.Semantic proximity
Select a neighboring publication to make it the new centre.